CD274 and non-small cell lung carcinoma: The previous studies have reported the improvement in ORR and DOR with the combination of pembrolizumab and PEM/platinum as first-line therapy in patients with metastatic non-squamous NSCLC, regardless of the PD-L1 expression levels [28, 35, 36].